Daptomycin: a novel cyclic lipopeptide antimicrobial.
OBJECTIVE
The development, activity, pharmacokinetics, pharmacodynamics, clinical efficacy, adverse effects, and dosage and administration of daptomycin are reviewed.


CONCLUSIONS
Daptomycin, a novel cyclic lipopeptide antimicrobial, is bactericidal against a range of gram-positive bacteria, including many multiple-drug-resistant isolates. It has only minimal activity against anaerobic bacteria and no activity against gram-negative bacteria. Daptomycin exhibits linear pharmacokinetics, and the plasma concentration-versus-time relationship is best described by a two-compartment model with first-order elimination. The initial bactericidal activity is rapid, extensive, and concentration related. In clinical trials, daptomycin has shown efficacy in treating complicated skin and skin-structure infections (CSSSIs); the drug carries FDA-approved labeling for same. The adverse effects of daptomycin appear comparable to those of vancomycin and semisynthetic penicillins. The dosage for CSSSIs is 4 mg/kg by i.v. infusion every 24 hours.


CONCLUSIONS
Daptomycin is bactericidal against gram-positive organisms and offers an option in the treatment of CSSSIs.
Schriever
Christopher A
CA
Loyal University Medical Center, Maywood, IL, USA.
Fernández
Cristina
C
Rodvold
Keith A
KA
Danziger
Larry H
LH
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D019540:Area Under Curve; D002986:Clinical Trials as Topic; D017576:Daptomycin / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D004347:Drug Interactions; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D008826:Microbial Sensitivity Tests
D000900:Anti-Bacterial Agents; D017576:Daptomycin